The EPIC cardiac substudy showed that Exjade removed iron from the heart in beta-thalassemia patients, based on a statistically significant improvement in T2* magnetic resonance imaging, a validated ...
EXJADE (deferasirox) 125mg, 250mg, 500mg tablets for oral suspension by Novartis Novartis announced that the FDA has approved Exjade (deferasirox tablets for oral suspension) for the treatment of ...
To earn CME related to this news article, click here. January 28, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the risk for effects on pacing or ...
These patients are detected with non-transfusion-dependent thalassemia (NTDTY) syndrome along with a liver iron concentration of at least 5 mg of iron per gram dry weight and a serum ferritin ...
EAST HANOVER, N.J., January 23, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Exjade ® (deferasirox) for the treatment of chronic iron ...
May 23, 2007 -- Renal failure and cytopenias have been reported in patients receiving deferasirox oral suspension tablets ( Exjade; Novartis Pharmaceuticals Corp), according to the US Food and Drug ...
The FDA has notified healthcare professional of an Early Communication regarding an ongoing review of safety issues with Exjade (deferasirox tablets for oral suspension, from Novartis). New safety ...
New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply ...
Switzerland based Novartis (NVS) recently announced the approval of Exjade (deferasirox) by the European Commission. Exjade has been approved for the treatment of chronic iron overload requiring ...
OLYMPIA, Wash. (Legal Newsline) – Washington Attorney General Bob Ferguson filed a motion on Wednesday to intervene in a civil lawsuit against Novartis Pharmaceuticals Corporation alleging the company ...
BALTIMORE (Legal Newsline) – Maryland Attorney General Douglas Gansler filed a civil lawsuit on Monday against Novartis Pharmaceuticals Corporation for allegedly paying kickbacks to a former national ...
Novartis ( NVS) recently announced that the US Food and Drug Administration (FDA) has approved Exjade (deferasirox) for the treatment of chronic iron overload in patients aged ten years and above.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results